Job Trends
In a competitive job market, how applicants present themselves in interviews is critical. Asking about promotions and expressing dislike for the work they’d be doing are just a few reasons hiring managers don’t extend job offers.
Labor Market Reports
BioSpace’s 2026 U.S. Life Sciences Employment Outlook examines the state of the biopharma workforce amid ongoing funding pressure, elevated layoffs and cautious hiring sentiment, while highlighting early signals of stabilization and cautious optimism for the year ahead.
BioSpace’s 2025 Q4 U.S. Life Sciences Job Market update highlights early signs of stabilization in biopharma hiring, with modest gains in job postings, slowing layoffs, and cautiously improving sentiment heading into 2026.
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
Now Hiring
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
Looking for an IT job? From data engineer to information security, check out the BioSpace list of 10 companies hiring life sciences professionals like you.
More biopharma organizations were actively recruiting at the end of 2025 than 2024, based on the new BioSpace employment outlook report. Areas in demand this year include research and development and clinical. Organizations are also prioritizing artificial intelligence hires.
Career Advice
With leaner teams and tighter budgets, senior leaders can face tremendous strain as they juggle increased workloads and leadership responsibilities. In this column, Kaye/Bassman’s Michael Pietrack discusses how pressure builds and what can ease it.
THE LATEST
Most investors and analysts are expecting 2018 to be a big year for mergers and acquisitions.
Sanofi has announced major restructuring, which will involve layoffs.
The deal has Sanofi paying $105 per share in cash.
The announcement sent shares of Juno soaring more than 27 percent in pre-market trading to $86.26.
Life sciences professionals don’t have to look far for opportunity in Genetown.
The survey of 51 oncologists suggests broad uptake of Imfinzi in advanced lung cancer patients who can’t be treated with surgery.
Astra has seen a fourfold increase in research productivity following a narrowing of disease focus and cuts in laboratory and staff over the past seven years, Reuters reported Thursday.
Shire will have its new CFO in March.
All of the recent problems have caused the company’s largest shareholder to push for a sale.
Fresh off its $7B acquisition, Celgene is planning to open a biopharma incubator on its corporate campus in New Jersey.